v3.26.1
Liabilities Related to Future Royalties and Milestones, Net - Schedule of Units of Accounting Recorded at Fair Value (Details) - BioNTech
$ in Millions
 12 Months Ended
Dec. 31, 2025
USD ($)
Class of Stock [Line Items]  
Payments of equity issuance costs $ 8.3
Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 250.0
Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 250.0
Allocated consideration based on relative fair value 250.0
Net allocated consideration based on relative fair value after transaction costs 241.7
Initial ADSs, representing ordinary shares | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 200.0
Initial ADSs, representing ordinary shares | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 200.0
Allocated consideration based on relative fair value 200.0
Net allocated consideration based on relative fair value after transaction costs 193.8
Subsequent ADSs, representing ordinary shares | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 0.0
Subsequent ADSs, representing ordinary shares | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 0.0
Allocated consideration based on relative fair value 0.0
Net allocated consideration based on relative fair value after transaction costs 0.0
BioNTech License and Option Agreement | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 50.0
BioNTech License and Option Agreement | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 50.0
Allocated consideration based on relative fair value 50.0
Net allocated consideration based on relative fair value after transaction costs 47.9
Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 40.0
Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 40.0
Allocated consideration based on relative fair value 40.0
Net allocated consideration based on relative fair value after transaction costs 38.3
License Revenue (Binder License) | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 10.0
License Revenue (Binder License) | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 10.0
Allocated consideration based on relative fair value 10.0
Net allocated consideration based on relative fair value after transaction costs 9.6
MCSA | Investor  
Class of Stock [Line Items]  
Amounts of related party transaction 0.0
MCSA | Investor | Estimate of Fair Value Measurement  
Class of Stock [Line Items]  
Amounts of related party transaction 0.0
Allocated consideration based on relative fair value 0.0
Net allocated consideration based on relative fair value after transaction costs $ 0.0